German Chancellor Angela Merkel in an interview on German television channel ARD on 2/2 mentioned the readiness of the vaccine COVID-19 in Russia.
|German Chancellor Angela Merkel said Germany considered the effective Russian Sputnik V vaccine. Photo: DW|
Accordingly, Ms. Merkel stressed that Germany welcomes all approved and tested vaccines to be effective in preventing COVID-19, regardless of which country the vaccine is made.
“All vaccines approved by the European Pharmaceutical Authority will be welcome. I talked to Russian President Putin about this and today we have all seen good data on Russian vaccines, ”Ms. Merkel stressed.
In Germany, Chancellor Angela Merkel pledged that, despite difficulties in the supply of vaccines, the German government still committed to vaccinating the entire German population by the third quarter of 2021. In the short term, Ms. Merkel pledged 10 million Germans will be vaccinated at the end of March 2021.
To meet this goal amid the complicated situation of US-German and UK vaccine orders, German Health Minister Jens Spahn said this week that Berlin would import the COVID-19 vaccine from Russia and China to compensate for the vaccine shortage under the Europe’s joint vaccination program.
“Any country that produces vaccines, if they are safe and effective, can help us cope with the pandemic,” said Germany’s Health Minister.
Mr. Spahn’s comments came after the Russian side, especially Russia’s permanent representative in the EU Vladimir Chizhov, announced that Moscow not only sells Sputnik V vaccine but is willing to share with the world how the vaccine is produced.
Mr. Chizhov said that Moscow will provide all interested countries with a vaccine trial before moving to the production of vaccines in that country.
The new Russian Sputnik V vaccine published by the world famous medical journal The Lancet is up to 91.6% effective.
It took many months for Russian immunologists and 19,866 volunteers to complete Phase III of a clinical trial that confirmed the vaccine efficacy was 91.6%.
Another important finding is the immunogenicity of the vaccine.
The 14,964 volunteers who received Sputnik V injections actually developed 1.3-1.5 times more antibodies against the new SARS-CoV-2 virus than those who recovered from COVID-19.
During the study, the remaining 4,902 participants received a placebo.
“The trial, which included a group of volunteers aged 60-87, showed impressive results for this elderly class. Surprisingly, the effect of Sputnik V in the elderly was comparable to that of the age group. 18-60, ie efficiency reaches 91.8% “- The Lancet assessed.
When it comes to safety, the Independent Data Monitoring Committee confirmed 94% of all side effects were mild. No serious side effects or product-related allergies have been detected, and most mild complications are limited to flu-like symptoms or headaches.
Ian Jones, an expert at the University of Reading and Polly Roy of the London School of Hygiene and Tropical Medicine, said in The Lancet: “The development of the Sputnik V vaccine has been criticized for being too hasty, staging and lack of However, the results reported here are clear and the scientific principles of the vaccination have been proven, meaning that more vaccines could be involved in the fight to reduce the incidence of COVID-19. “
Sputnik V, named after the Soviet-era satellite, was approved in Russia months before the release of the final stage clinical trial, leading to skepticism from experts.
However, the results of the new analysis show that Sputnik V is one of the most effective vaccines, along with vaccines from Pfizer / BioNTech and Moderna. These are the three vaccines in the world that are now more than 90% effective.